Prof. Dr. Martin Früh
Stv. Chefarzt
Leitung Fachbereich Onkologie
Medizinische Onkologie und Hämatologie · Dept. I
Management of Stage III Non-Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights.
Singh N, Früh M, Gubens M, Ismaila N, Daly M. Management of Stage III Non-Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights. JCO Oncol Pract 2024:OP2400784.
18.11.2024Management of Stage III Non-Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights.
18.11.2024JCO Oncol Pract 2024:OP2400784
Singh Navneet, Früh Martin, Gubens Matthew A, Ismaila Nofisat, Daly Megan E
Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment.
Schmid S, Holer L, Gysel K, Koster K, Rothschild S, Boos L, Frehner L, Cardoso Almeida S, Britschgi C, Metaxas Y, Mark M, Froesch P, Janthur W, Allemann A, Waibel C, Von der Mühll-Schill C, Früh M, Mauti L. Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment. JTO Clin Res Rep 2024; 5:100735.
15.10.2024Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment.
15.10.2024JTO Clin Res Rep 2024; 5:100735
Schmid Sabine, Holer Lisa, Gysel Katrin, Koster Kira-Lee, Rothschild Sacha I, Boos Laura A, Frehner Lorenz, Cardoso Almeida Sabine, Britschgi Christian, Metaxas Yannis, Mark Michael, Froesch Patrizia, Janthur Wolf-Dieter, Allemann Anna, Waibel Christine, Von der Mühll-Schill Catherine, Früh Martin, Mauti Laetitia A
Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade.
Wyss N, Berner F, Walter V, Jochum A, Purde M, Abdou M, Sinnberg T, Hofmeister K, Pop O, Hasan A, Bauer J, Cheng H, Lütge M, Klümper N, Diem S, Kosaloglu-Yalcin Z, Zhang Y, Sellmer L, Macek B, Karbach J, König D, Läubli H, Zender L, Meyer B, Driessen C, Schürch C, Jochum W, Amaral T, Heinzerling L, Cozzio A, Hegazy A, Schneider T, Brutsche M, Sette A, Lenz T, Walz J, Rammensee H, Früh M, Jäger E, Becher B, Tufman A, Núñez N, Jörger M, Flatz L. Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade. Am J Respir Crit Care Med 2024; 210:919-930.
01.10.2024Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade.
01.10.2024Am J Respir Crit Care Med 2024; 210:919-930
Wyss Nina, Berner Fiamma, Walter Vincent, Jochum Ann-Kristin, Purde Mette T, Abdou Marie-Therese, Sinnberg Tobias, Hofmeister Kathrin, Pop Oltin, Hasan Ali, Bauer Jens, Cheng Hung-Wei, Lütge Mechthild, Klümper Niklas, Diem Stefan, Kosaloglu-Yalcin Zeynep, Zhang Yizheng, Sellmer Laura, Macek Boris, Karbach Julia, König David, Läubli Heinz, Zender Lars, Meyer Britta S, Driessen Christoph, Schürch Christian M, Jochum Wolfram, Amaral Teresa, Heinzerling Lucie M, Cozzio Antonio, Hegazy AhN, Schneider Tino, Brutsche Martin, Sette Alessandro, Lenz Tobias L, Walz Juliane Sarah, Rammensee Hans-Georg, Früh Martin, Jäger Elke, Becher Burkhard, Tufman Amanda, Núñez Nicolás Gonzalo, Jörger Markus, Flatz Lukas
Prolonged Response to Afatinib and Crizotinib in a Rare Case of -, -, - and -Alterated Lung Adenocarcinoma.
Plomer E, Früh M, Lauber A, Demmer I, Jochum W, Koster K. Prolonged Response to Afatinib and Crizotinib in a Rare Case of -, -, - and -Alterated Lung Adenocarcinoma. Int J Mol Sci 2024; 25
23.05.2024Prolonged Response to Afatinib and Crizotinib in a Rare Case of -, -, - and -Alterated Lung Adenocarcinoma.
23.05.2024Int J Mol Sci 2024; 25
Plomer Eva, Früh Martin, Lauber Arno, Demmer Izadora, Jochum Wolfram, Koster Kira-Lee
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.
Mark M, Froesch P, Gysel K, Rothschild S, Addeo A, Ackermann C, Chiquet S, Schneider M, Ribi K, Maranta A, Bastian S, von Moos R, Jörger M, Früh M, Swiss Group for Clinical Cancer Research (SAKK). First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17. Eur J Cancer 2024; 200:113600.
05.02.2024First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.
05.02.2024Eur J Cancer 2024; 200:113600
Mark Michael, Froesch Patrizia, Gysel Katrin, Rothschild Sacha I, Addeo Alfredo, Ackermann Christoph Jakob, Chiquet Sabrina, Schneider Martina, Ribi Karin, Maranta Angela Fischer, Bastian Sara, von Moos Roger, Jörger Markus, Früh Martin, Swiss Group for Clinical Cancer Research (SAKK)
Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.
Schuler A, Huser J, Schmid S, Schär S, Scherz A, Gautschi O, Mauti L, von Briel T, Waibel C, Wannesson L, Pankovics J, Mark M, Rothschild S, Addeo A, Janthur W, Siano M, Boos L, Britschgi C, Früh M. Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study. Lung Cancer 2023; 187:107427.
22.11.2023Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.
22.11.2023Lung Cancer 2023; 187:107427
Schuler Alexandra, Huser J, Schmid Sebastian M, Schär Sämi, Scherz Amina, Gautschi Oliver Pascal, Mauti Laetitia A, von Briel Thomas, Waibel Christine, Wannesson Luciano, Pankovics J, Mark Michael Thomas, Rothschild Sacha I, Addeo Alfredo, Janthur W, Siano Marco, Boos L, Britschgi Christian, Früh Martin
A Literature Review of Racial Disparities in Prostate Cancer Research.
Vermeille M, Koster K, Benzaquen D, Champion A, Taussky D, Kaulanjan K, Früh M. A Literature Review of Racial Disparities in Prostate Cancer Research. Curr Oncol 2023; 30:9886-9894.
12.11.2023A Literature Review of Racial Disparities in Prostate Cancer Research.
12.11.2023Curr Oncol 2023; 30:9886-9894
Vermeille Matthieu, Koster Kira-Lee, Benzaquen David, Champion Ambroise, Taussky Daniel, Kaulanjan Kevin, Früh Martin
Non-pharmaceutical interventions to optimize cancer immunotherapy.
Bösch M, Baty F, Rassouli F, Kowatsch T, Jörger M, Früh M, Brutsche M. Non-pharmaceutical interventions to optimize cancer immunotherapy. Oncoimmunology 2023; 12:2255459.
28.09.2023Non-pharmaceutical interventions to optimize cancer immunotherapy.
28.09.2023Oncoimmunology 2023; 12:2255459
Bösch Maximilian, Baty Florent, Rassouli Frank, Kowatsch Tobias, Jörger Markus, Früh Martin, Brutsche Martin
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.
König D, Savic Prince S, Hayoz S, Zens P, Berezowska S, Jochum W, Stauffer E, Braunersreuther V, Trachsel B, Thierstein S, Mark M, Schmid S, Curioni-Fontecedro A, Addeo A, Schmitt-Opitz I, Guckenberger M, Früh M, Betticher D, Ris H, Stupp R, Rothschild S, Bubendorf L, Pless M. Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14. ESMO Open 2023; 8:101595.
11.07.2023Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.
11.07.2023ESMO Open 2023; 8:101595
König Dietmar-Pierree, Savic Prince Spasenija, Hayoz Stefanie, Zens P, Berezowska Sabina, Jochum Wolfram, Stauffer Edouard, Braunersreuther V, Trachsel B, Thierstein Sandra, Mark Michael Thomas, Schmid Sebastian M, Curioni-Fontecedro Alessandra, Addeo Alfredo, Schmitt-Opitz Isabelle, Guckenberger Matthias, Früh Martin, Betticher Daniel C, Ris H B, Stupp Roger, Rothschild Sacha I, Bubendorf Lukas, Pless Miklos
Unusually Aggressive Presentation of Malignant Peritoneal Mesothelioma: Two Case Reports.
Neff D, Padberg Sgier B, Dietze H, Müller J, Früh M. Unusually Aggressive Presentation of Malignant Peritoneal Mesothelioma: Two Case Reports. Case Rep Oncol 2022; 15:1001-1008.
08.11.2022Unusually Aggressive Presentation of Malignant Peritoneal Mesothelioma: Two Case Reports.
08.11.2022Case Rep Oncol 2022; 15:1001-1008
Neff Dominik, Padberg Sgier Barbara-Christina, Dietze Hannah, Müller Joachim, Früh Martin
Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma.
Sun S, Qi W, Rehrauer H, Ronner M, Hariharan A, Wipplinger M, Meiller C, Stahel R, Früh M, Cerciello F, Fonteneau J, Jean D, Felley-Bosco E. Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma. JTO Clin Res Rep 2022; 3:100430.
07.11.2022Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma.
07.11.2022JTO Clin Res Rep 2022; 3:100430
Sun Suna, Qi Weihong, Rehrauer Hubert, Ronner Manuel, Hariharan Ananya, Wipplinger Martin, Meiller Clément, Stahel Rolf, Früh Martin, Cerciello Ferdinando, Fonteneau Jean-François, Jean Didier, Felley-Bosco Emanuela
Call for a holistic framework for cancer immunotherapy.
Boesch M, Baty F, Kowatsch T, Wolf D, Früh M, Brutsche M. Call for a holistic framework for cancer immunotherapy. Cancer 2022; 128:3772-3774.
15.09.2022Call for a holistic framework for cancer immunotherapy.
15.09.2022Cancer 2022; 128:3772-3774
Boesch Maximilian, Baty Florent, Kowatsch Tobias, Wolf Dominik, Früh Martin, Brutsche Martin H
Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.
Berner F, Bomze D, Lichtensteiger C, Walter V, Niederer R, Hasan Ali O, Wyss N, Bauer J, Freudenmann L, Marcu A, Wolfschmitt E, Haen S, Gross T, Abdou M, Diem S, Knöpfli S, Sinnberg T, Hofmeister K, Cheng H, Toma M, Klümper N, Purde M, Pop O, Jochum A, Pascolo S, Jörger M, Früh M, Jochum W, Rammensee H, Läubli H, Hölzel M, Neefjes J, Walz J, Flatz L. Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. Sci Immunol 2022; 7:eabn9644.
02.09.2022Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.
02.09.2022Sci Immunol 2022; 7:eabn9644
Berner Fiamma, Bomze David, Lichtensteiger Christa, Walter Vincent, Niederer Rebekka, Hasan Ali Omar, Wyss Nina, Bauer Jens, Freudenmann Lena Katharina, Marcu Ana, Wolfschmitt Eva-Maria, Haen Sebastian, Gross Thorben, Abdou Marie-Therese, Diem Stefan, Knöpfli Stella, Sinnberg Tobias, Hofmeister Kathrin, Cheng Hung-Wei, Toma Marieta, Klümper Niklas, Purde Mette-Triin, Pop Oltin Tiberiu, Jochum Ann-Kristin, Pascolo Steve, Jörger Markus, Früh Martin, Jochum Wolfram, Rammensee Hans-Georg, Läubli Heinz, Hölzel Michael, Neefjes Jacques, Walz Juliane, Flatz Lukas
Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.
Addeo A, Rothschild S, Holer L, Schneider M, Waibel C, Haefliger S, Mark M, Fernandez E, Mach N, Mauti L, Jermann P, Alborelli I, Calgua B, Savic-Prince S, Joerger M, Früh M. Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. Lung Cancer 2022; 172:154-159.
28.08.2022Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.
28.08.2022Lung Cancer 2022; 172:154-159
Addeo Alfredo, Rothschild Sacha I, Holer Lisa, Schneider Martina, Waibel Christine, Haefliger Simon, Mark Michael, Fernandez Eugenio, Mach Nicolas, Mauti Laetitia, Jermann Philip, Alborelli Ilaria, Calgua Byron, Savic-Prince Spasenija, Joerger Markus, Früh Martin
Sotorasib Shows Intracranial Activity in Patients with Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases.
Koster K, Appenzeller C, Lauber A, Früh M, Schmid S. Sotorasib Shows Intracranial Activity in Patients with Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases. Case Rep Oncol 2022; 15:720-725.
26.08.2022Sotorasib Shows Intracranial Activity in Patients with Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases.
26.08.2022Case Rep Oncol 2022; 15:720-725
Koster Kira-Lee, Appenzeller Christina, Lauber Arno, Früh Martin, Schmid Sabine
Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment.
Furrer K, Weder W, Eboulet E, Betticher D, Pless M, Stupp R, Krueger T, Perentes J, Schmid R, Lardinois D, Furrer M, Früh M, Peters S, Curioni-Fontecedro A, Stahel R, Rothschild S, Hayoz S, Opitz I. Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment. J Thorac Cardiovasc Surg 2022; 164:1587-1602.e5.
18.04.2022Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment.
18.04.2022J Thorac Cardiovasc Surg 2022; 164:1587-1602.e5
Furrer Katarzyna, Weder Walter, Eboulet Eric Innocents, Betticher Daniel, Pless Miklos, Stupp Roger, Krueger Thorsten, Perentes Jean Yannis, Schmid Ralph A, Lardinois Didier, Furrer Markus, Früh Martin, Peters Solange, Curioni-Fontecedro Alessandra, Stahel Rolf A, Rothschild Sacha I, Hayoz Stefanie, Opitz Isabelle
Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline.
Daly M, Singh N, Ismaila N, Antonoff M, Arenberg D, Bradley J, David E, Detterbeck F, Früh M, Gubens M, Moore A, Padda S, Patel J, Phillips T, Qin A, Robinson C, Simone C. Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline. J Clin Oncol 2021; 40:1356-1384.
22.12.2021Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline.
22.12.2021J Clin Oncol 2021; 40:1356-1384
Daly Megan E, Singh Navneet, Ismaila Nofisat, Antonoff Mara B, Arenberg Douglas A, Bradley Jeffrey, David Elizabeth, Detterbeck Frank, Früh Martin, Gubens Matthew A, Moore Amy C, Padda Sukhmani K, Patel Jyoti D, Phillips Tanyanika, Qin Angel, Robinson Clifford, Simone Charles B
Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer.
Bösch M, Baty F, Albrich W, Flatz L, Rodriguez R, Rothschild S, Jörger M, Früh M, Brutsche M. Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer. Oncoimmunology 2021; 10:1988403.
10.12.2021Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer.
10.12.2021Oncoimmunology 2021; 10:1988403
Bösch Maximilian, Baty Florent, Albrich Werner, Flatz Lukas, Rodriguez Regulo, Rothschild Sacha I, Jörger Markus, Früh Martin, Brutsche Martin H
Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
Purde M, Niederer R, Wagner N, Diem S, Berner F, Hasan Ali O, Hillmann D, Bergamin I, Jörger M, Risch M, Niederhauser C, Lenz T, Früh M, Risch L, Semela D, Flatz L. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. J Cancer Res Clin Oncol 2021; 148:647-656.
07.12.2021Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
07.12.2021J Cancer Res Clin Oncol 2021; 148:647-656
Purde Mette-Triin, Niederer Rebekka, Wagner Nikolaus, Diem Stefan, Berner Fiamma, Hasan Ali Omar, Hillmann Dorothea, Bergamin Irina, Jörger Markus, Risch Martin, Niederhauser Christoph, Lenz Tobias L, Früh Martin, Risch Lorenz, Semela David, Flatz Lukas
Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival.
Berner F, Niederer R, Luimstra J, Pop O, Jochum A, Purde M, Hasan Ali O, Bomze D, Bauer J, Freudenmann L, Marcu A, Wolfschmitt E, Haen S, Gross T, Dubbelaar M, Abdou M, Baumgaertner P, Appenzeller C, Cicin-Sain C, Lenz T, Speiser D, Ludewig B, Driessen C, Jörger M, Früh M, Jochum W, Cozzio A, Rammensee H, Walz J, Neefjes J, Flatz L. Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival. Oncoimmunology 2021; 10:2006893.
27.11.2021Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival.
27.11.2021Oncoimmunology 2021; 10:2006893
Berner Fiamma, Niederer Rebekka, Luimstra Jolien J, Pop Oltin Tiberiu, Jochum Ann-Kristin, Purde Mette-Triin, Hasan Ali Omar, Bomze David, Bauer Jens, Freudenmann Lena Katharina, Marcu Ana, Wolfschmitt Eva-Maria, Haen Sebastian, Gross Thorben, Dubbelaar MariLisa, Abdou Marie-Therese, Baumgaertner Petra, Appenzeller Christina, Cicin-Sain Caroline, Lenz Tobias, Speiser Daniel E, Ludewig Burkhard, Driessen Christoph, Jörger Markus, Früh Martin, Jochum Wolfram, Cozzio Antonio, Rammensee Hans-Georg, Walz Juliane, Neefjes Jacques, Flatz Lukas